Erythrocyte membranes beta-adrenoreactivity changes after renal denervation in patients with resistant hypertension, relationship with antihypertensive and cardioprotective intervention efficacy

Aim      To study the functional condition of sympathoadrenal system as evaluated by beta-adrenoreactivity of erythrocyte membranes (beta-ARM) during two years following renal denervation (RD) in patients with resistant arterial hypertension (RAH) and to determine the relationship of this index with long-term antihypertensive and cardioprotective effectivity of this invasive treatment.

Material and methods  The study included 48 patients (mean age, 57.2±8.7 years, 18 men) with RAH on a stable antihypertensive therapy. Averaged daily systolic and diastolic blood pressure (SBP and DBP) and levels of beta-ARM were determined at baseline and in 7 days and 2 years following RD. Measurement of beta-ARM was based on beta-adrenoblocker inhibition of erythrocyte hemolysis induced by exposure to hypo-osmotic environment. The beta-adrenoblocker binds to erythrocyte membrane beta-adrenoceptors to prevent the erythrocyte destruction. Increased values of beta-ARM reflect a decrease in the number of functionally active erythrocyte membrane beta-adrenoceptors associated with long-term sympathetic hyperactivity.

Results For two years of follow-up, values of average daily BP decreased from 160.4±16.0 / 88.1±14.6 to 145.3±19.3 / 79.4±13.6 mm Hg. At 7 days, the number of beta-ARM had decreased in the group of RD responders (р=0.028) who at two years had decreased their BP by 10 mm Hg or more, while in the group of non-responders, the number of beta-ARM remained unchanged. At one week, beta-ARM values correlated with changes in SBP and DBP (r= –0.54; р<0.05) and with left ventricular myocardial mass (LVMM) (r= –0.36; р<0.05) at two years of follow-up whereas beta-ARM delta at one week was interrelated with the renin concentration in the long-term (r= –0.44; р<0.05). At two years, the content of beta-ARM was increased in both groups.

Conclusion      The decrease in beta-ARM content at 7 days after RD shows the procedure efficacy and allows an expectation of clinically significant decreases in BP and LVMM in the long-term after the surgical treatment. At two years after the intervention, the content of beta-ARM increased, and the BP decrease was apparently due to some other mechanisms.

1. Weber MA, Mahfoud F, Schmieder RE, Kandzari DE, Tsioufis KP, Townsend RR at al. Renal denervation for treating hypertension: current scientific and clinical evidence. JACC: Cardiovascular Interventions. 2019;12(12):1095-1105. https://doi.org/10.1016/j.jcin.2019.02.050

2. Zyubanova I.V., Mordovin V.F., Falkovskaja A.Y., Pekarsky S.E. CHANGES IN AMBULATORY BLOOD PRESSURE MONITORING DATA AFTER RENAL DENERVATION: 12-MONTH FOLLOW-UP. The Siberian Journal of Clinical and Experimental Medicine. 2015;30(3):41-44. (In Russ.) https://doi.org/10.29001/2073-8552-2015-30-3-41-44

3. Saveleva N.Yu., Zherzhova A.Yu., Mikova E.V., Gapon L.I., Kolunin G.V., Krinochkin D.V. Radiofrequency denervation of the renal arteries in patients with resistant arterial hypertension: three-year follow-up experience. Systemic hypertension. 2019;16(4):65-69. (In Russ.) https://doi.org/10.26442/2075082X.2019.4.190596

4. Falkovskaya A.Yu., Mordovin V.F., Pekarskiy S.E., Ripp T.M., Lichikaki V.A., Sitkova E.S., Zyubanova I.V., Suslova T.E., Gusakova A.M., Baev A.E., Manukyan M.А., Buhkarova E.K. The effects of renal denervation on adipokines and pro-inflammatory status in patients with resistant arterial hypertension associated with type 2 diabetes mellitus. The Siberian Journal of Clinical and Experimental Medicine. 2019;34(4):118-127. (In Russ.) https://doi.org/10.29001/2073-8552-2019-34-4-118-127

5. Frolova E.V., Vachev A.N., Morkovskikh N.V., Koryttsev V.K. Selection of Patients with Resistant Arterial Hypertension for the Catheter-Based Renal Sympathetic Denervation. Kardiologiia. 2019;59(4):21-25. (In Russ.) https://doi.org/10.18087/cardio.2019.4.10234

6. Chichkova T.Y., Mamchur S.E., Khomenko E.A., Romanova M.P., Mamchur I.N., Trishkina N.N. SELECTION OF PATIENTS WITH RESISTANT ARTERIAL HYPERTENSION FOR RENAL DENERVATION. Complex Issues of Cardiovascular Diseases. 2017;6(4):80-88. (In Russ.) https://doi.org/10.17802/2306-1278-2017-6-4-80-88

7. Ripp T.M., Rebrova T.Yu., Mordovin V.F., Afanasev S.A., Pekarskij S.E., Semke G.V. at al. Selection criteria for patients with resistant arterial hypertension for sympathetic renal denervation. Therapeutic archive. 2016;88(8):14-18. (In Russ.) doi: 10.17116/terarkh201688814-18

8. Rebrova T.Yu., Ripp T.M., Afanasev S.A., Mordovin V.F., Muslimova Eh. F. Possibility of evaluating the effectiveness of sympathetic denervation of the renal arteries in resistant arterial hypertension early after radiofrequency ablation. Therapeutic archive. 2016;88(8):10-13. (In Russ.) doi:10.17116/terarkh201688810-13

9. Stryuk R.I., Dlusskaya I.G. Adrenoreactivity and cardiovascular system. M: Medicine, 2003. p. 160. (In Russ.) ISBN: 5-225-04337-2

10. Vorobyova D.A., Rebrova T.Yu., Afanasyev S.A., Ryabov V.V. Comparative analysis of adrenergic reactivity of erythrocytes in patients with myocardial infarction depending on the severity of coronary obstruction. Russian Journal of Cardiology. 2020;25(5):3735. (In Russ.) https://doi.org/10.15829/1560-4071-2020-3735

11. Garganeeva A.A., Aleksandrenko V.A., Kuzheleva E.A., Rebrova T.Yu. Beta-adrenergic reactivity of erythrocytes and the progression of heart failure in patients after myocardial infarction. Russian Journal of Cardiology. 2020;25(1):3407. (In Russ.) https://doi.org/10.15829/1560-4071-2020-1-3407

12. Borisova E.V., Afanasev S.A., Rebrova T.Yu., Kisteneva I.V., Batalov R.E., Popov S.V. Changes in adrenoreactivity in patients with paroxysmal atrial fibrillation while taking sotalol, depending on the tone of the autonomic nervous system. Therapeutic archive. 2016;88(1):35-39. (In Russ.) DOI: 10.17116/terarkh201688135-39

13. Arterial hypertension in adults. Clinical guidelines 2020. Russian journal of cardiology. 2020;25(3):3786. (In Russ.) doi:10.15829/1560-4071-2020-3-3786.

14. Doroszko A, Janus A, Szahidewicz-krupska E, Mazur G, Derkacz A. Resistant hypertension. Adv Clin Exp med. 2016;25(1):173-83. doi: 10.17219/acem/58998

15. Townsend RR, Mahfoud F, Kandzari DE, Kario K, Pocock S, Weber MA et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (spyral htn-off med): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017;390(10108):2160–70.

16. Zyubanova I.V., Mordovin V.F., Pekarskiy S.E., Ripp T.M., Falkovskaya A.Yu., Lichikaki V.A., Sitkova E.S., Baev A.E., Gusakova A.M., Ryabova T.R. Possible mechanisms of renal denervation long-term cardiac effects. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2019;25(4):423-432. (In Russ.) https://doi.org/10.18705/1607-419X-2019-25-4-423-432

17. Barsukov A.V., Gluhovskoj D.V., Talanceva M.S., Bagaeva Z.V., Pronina E.V., Zobnina M.P. at al. Left ventricular hypertrophy and the renin-angiotensin-aldosterone system: AT1-angiotensin receptor blockers in focus. Systemic hypertension. 2013;01:88-96. (In Russ.) ISSN: 2075-082XeISSN: 2542-2189